

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI615339

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
James M. Cook	11/05/2020
Guanguan Li	03/31/2017
Michael Ming-Jin Poe	03/31/2017
RECEIVING PARTY DATA	
Company Name:	UWM Research Foundation, Inc.
Street Address:	1440 East North Avenue
City:	Milwaukee
State/Country:	WISCONSIN
Postal Code:	53202
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	18363933
CORRESPONDENCE DATA	
Fax Number:	4142770656
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(414)271-6560
Email:	mkeipdocket@michaelbest.com,dahauser@michaelbest.com
Correspondent Name:	Dorothy A. Hauser
Address Line 1:	Michael Best & Friedrich LLP
Address Line 2:	N19 W24133 Riverwood Drive, Ste. 200
Address Line 4:	Waukesha, WISCONSIN 53188
ATTORNEY DOCKET NUMBER:	020871-9121-US03
NAME OF SUBMITTER:	Dorothy Hauser
SIGNATURE:	Dorothy Hauser
DATE SIGNED:	11/06/2024
Total Attachments: 4	
source=020871-9121-US03_As_Filed_Assignment_Cook_Li_Poe#page1.tiff	
source=020871-9121-US03_As_Filed_Assignment_Cook_Li_Poe#page2.tiff	
source=020871-9121-US03_As_Filed_Assignment_Cook_Li_Poe#page3.tiff	

ASSIGNMENT

Pursuant to our obligation to UWM Research Foundation, Inc. (hereinafter referred to as "Assignee"), a Wisconsin non-stock, non-profit corporation having its principal place of business at:

1440 East North Avenue
Milwaukee, WI 53202

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

James M. Cook
6139 N. Lake Drive
Milwaukee, WI 53217

Guanguan Li
2020 E. Park Place, Apartment 104
Milwaukee, WI 53211

Michael Ming-Jin Poe
2921 Bronson Boulevard
Kalamazoo, MI 49008

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest

(1) in and to inventions described in a patent application titled TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS the specification of which was filed with our authority on September 18, 2018, as International Patent Application No. PCT/US2017/023206 (Atty. File No. 020871-9121-WO01) (hereinafter the "PCT application"), which application claims the benefit of United States Provisional Patent Application No. 62/310,409, filed March 18, 2016 (hereinafter the "U.S. provisional patent application");

(2) in and to the PCT application and the U.S. provisional patent application, in and to all other U.S. patent applications (including PCT national phase, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue applications) based upon said inventions or claiming the benefit of the PCT application, or the U.S. provisional patent application, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, including foreign applications entering the national phase of the PCT application, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the PCT application and the U.S. provisional patent application.

We agree that any patent applications of any foreign countries which may be filed shall be filed in the name of Assignee with a claim to priority based on the PCT application and the U.S. provisional patent application. We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

11/05/2020

Date



James M. Cook

Date

Guanguan Li

Date

Michael Ming-Jin Poe

ASSIGNMENT

Pursuant to our obligation to UWM Research Foundation, Inc. (hereinafter referred to as "Assignee"), a Wisconsin non-stock, non-profit corporation having its principal place of business at:

1440 East North Avenue
Milwaukee, WI 53202

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

James Cook
6139 N Lake Drive
Milwaukee, WI 53217

Michael Ming-jin Poe
1100 Hartford Turnpike, Apt. 548
Vernon, CT 06066

Guanguan Li
2020 E Park PL, Apt 104,
Milwaukee WI 53211

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest -

(1) in and to inventions described in a patent application titled "TREATMENTS OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA SELECTIVE AGONISTS" for which we filed International Patent Application No. PCT/US2017/023206, (Atty. File No. 020871-9121-WO00) (hereinafter the "PCT patent application") which application claims the benefit of United States Provisional Patent Application No. 62/310,409, filed March 18, 2016 (hereinafter the "U.S. provisional patent application") (Atty. File No. 020871-9121-US00);

;

(2) in and to the PCT patent application, and the U.S. provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, 35 U.S.C. §111(b) provisional, 35 U.S.C. §111(a), and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the PCT patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on the PCT patent application and the U.S. provisional patent application.

We hereby authorize the assignee or attorney of record to insert in the appropriate place in this document the application number of our application after execution of this Assignment. We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.

Date

James M Cook

3/31/2017

Date

Michael Ming-jin Poe

Michael Ming-Jin Poe

3/31/2017

Date

Guanguan Li

Guanguan Li